anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background and Objectives: Surgical site infections (SSIs) are a significant complication following ventral hernia repair, potentially leading to prolonged hospital stays and increased morbidity. This study aimed to evaluate whether closed incision negative pressure wound therapy (ciNPWT) reduces the incidence of SSI after ventral hernia repair with polypropylene mesh compared to standard wound care. Materials and Methods: A randomized study was conducted with 100 patients undergoing ventral hernia repair using a polypropylene mesh. Participants were divided into two groups: a control group (n=50), which received standard sterile gauze dressing with an iodine-based disinfectant, and an intervention group (n=50), treated with the ciNPWT system (Vivano® by HARTMANN) for 5 days postoperatively. The primary outcome was the incidence of SSI within one year after surgery. Secondary outcomes included the influence of factors such as age, sex, smoking status, and hernia size on SSI occurrence. The study was approved by the Ethics Committee at the University Hospital Ostrava, adhering to the ethical standards of the Helsinki Declaration. Results: The incidence of SSI was lower in the ciNPWT group compared to the standard care group (4% vs. 12%), though this difference did not reach statistical significance. No significant effect of sex or smoking status on SSI was observed. The control group had a shorter mean length of hospital stay. Larger hernias in the non-ciNPWT group were more prone to SSIs, as expected. Conclusions: Although limited by a small sample size, the findings suggest that ciNPWT may be associated with a reduced rate of SSI following ventral hernia repair. Further studies with larger populations are needed to confirm these results.
To provide a novel pharmacological potency of polymeric polyphenol. A polymeric polyphenol of 9000 to 18,000 number average molecular weight extracted from a fermented tea (oolong, red tea, etc.), comprising a partial structure wherein there are contained a procyanidin structure resulting from polymerization of a catechin and/or a gallic ester thereof as well as a structure resulting from bonding of B-rings of catechins and/or gallic esters thereof. This polymeric polyphenol exhibits a mitochondria activating potency, a hyperglycemia inhibiting potency, a body weight gain inhibiting potency, etc. Therefore, it can be used as a therapeutic agent for mitochondrial diseases and as a preventive/therapeutic agent for diabetes mellitus. Further, the polymeric polyphenol may be incorporated in a health food or beverage, etc. The selected figure shows the change of blood sugar level exhibited when indicated amounts of the polymeric polyphenol have been administered to diabetic model mice on a daily basis.
The invention relates to a three-part injectable composition comprising Docetaxel in a surface active agent and an additive to prevent gelling on dilution and diluents. It includes a matrix solution, an anti-agglutination agent prevent the injectable composition from agglutination and a flow agent facilitate the flowing of the matrix solution. The matrix solution includes the Docetaxel and one or more medically acceptable surfactants. First, the matrix is well mixed with the anti-agglutination agent, and then the flow agent is added and well mixed. The three-part injectable composition can be homogeneous and not agglutination, so that the health care provider can easily obtain the injectable composition through a needle and confirm the amount of suction. In addition, it can delay the time of Docetaxel crystallization, so that the stability of the injectable composition is increased. Patients can prevent lethal dangerous for accepting the composition and improve the health care quality.
The invention relates to a pure natural wild Chinese medicinal herb special for treating mammary gland diseases such as breast cancers, proliferation and tumor enclosed mass of mammary glands and the like. Due to the emergence of a traditional Chinese medicine special for treating breast cancers, the cruel reality that the breast cancers are treated by extirpating single or double breasts of women surgically in the medical field at present, but majority of patients still die is changed. The breast cancers have extremely-high grade malignancy and is quick in metastasis, and often perform mutual metastasis between uterus and breasts of the women, so the patients who suffer from the breast cancers can be cured as long as persisting in taking 'breast indurated goiter health' within a few months! In the treatment process, the intolerable pain of the breast cancers can be relieved or removed greatly within a few days, and the breast cancers can be cured after 4 to 6 months; and the breasts of the patients are kept intact, the natural and svelte physical condition of the vast women who suffer from the breast cancers is kept without damaged, and the personalistic dignity of the women is maintained. In addition, Chinese medicinal materials used by the traditional Chinese medicine are wide in medicinal sources, can be purchased throughout the country and have low cost, and common people can afford the traditional Chinese medicine. Therefore, the traditional Chinese medicine special for treating breast cancers is the first choice of the vast patients who suffer from breast cancers.
Participants in this arm will undergo coronary intervention using a 6F thin-walled sheath via distal radial artery access. This group will serve as the control to compare the outcomes against those of the 7F sheath group.
PURPOSE: The oral cavity and, in particular, potential oral foci might pose a risk of periprosthetic joint infection (PJI). The aim of this cohort study was to determine whether practical preoperative dental screening would reduce the prevalence of early PJI in the first month after surgery.
METHODS: Patients attending a specialized endoprosthesis implantation clinic between 2018 and 2022 were recruited. Two groups were examined. The test group consisted of patients attending the clinic between 2020 and 2022 and who were referred to their family dentist using a standardized form. The comparison group consisted of patients who were treated in the clinic between 2018 and 2020. They were not referred to their family dentist. The two groups were compared for the prevalence of PJI. Univariate analysis followed by multiple logistic regression was performed to confirm risk factors for PJI in this cohort.
RESULTS: 2560 individuals (test group: 1227, comparison group: 1333) were included. The prevalence of PJI was significantly lower in the test group (0.8% vs. 1.8%, p = 0.04). Multiple logistic regression with PJI as the dependent variable showed that a dental referral was a strong predictor of a lower prevalence of PJI (OR: 0.43, CI95 0.205-0.917, p = 0.03). Male gender was also strongly associated with a higher frequency of PJI (OR: 2.68, CI95 1.32-5.42, p = 0.01). Age (OR: 1.06, CI95 1.01-1.10, p = 0.01) and BMI (OR: 1.11, CI95 1.05-1.17, p < 0.01) had little effect on the risk of PJI.
CONCLUSION: Dental referral using a standardized form can reduce the prevalence of early PJI. Accordingly, orthopedists and dentists should collaborate in this practical way.
Unveiling of the mechanism involved in the occurrence and development of trauma-induced heterotopic ossification (tHO) is highly demanding due to current ineffective clinical treatment for it. Previous studies proposed that hydrogen sulfide (H2S) was vital for fate determination of stem cells, suggesting a potential role in the regulation of tHO development. In the current study, We found that expression of metabolic enzyme within sulfur conversion pathway was enhanced after tendon injury, leading to H2S accumulation within the tHO region. Increased production of endogenous H2S was shown to promote aberrant osteogenic activity of tendon-derived stem cells (TDSCs), which accelerated tHO formation. The inhibition of metabolic enzyme of H2S production or directly absorption of H2S could abolished osteogenic induction of TDSCs and the formation of tHO. Mechanistically, through RNA sequencing combined with rescue experiments, we demonstrated that activation of Ca2+/ERK pathway was the downstream molecular event of H2S-induced osteogenic commitment of TDSCs and tHO. For treatment strategy exploration, zine oxide nanoparticles (ZnO) as an effective H2S elimination material was validated to ideally halt the tHO formation in this study. Furthermore, in terms of chirality of nanoparticles, D-ZnO or L-ZnO nanoparticles showed superiority over R-ZnO nanoparticles in both clearing of H2S and inhibition of tHO. Our study not only revealed the mechanism of tHO through the endogenous gas signaling event from a new perspective, but also presented a applicable platform for elimination of the inordinate gas production, thus aiding the development of clinical treatment for tHO.
This is a multi-center, randomized, double-blind, sham-controlled crossover clinical trial conducted on subjects with painful peripheral diabetic neuropathy. Eligible subjects will include those between 22 and 80 years of age with Type 2 diabetes having persistent pain, numbness, tingling, and/or burning in at least one foot. Pain threshold, tolerance to thermal stimuli and pressure response to the induced pain stimuli will be measured at three time points using five standardized experimental pain measures: baseline, after a single 30 minute treatment with active PEMF or sham treatment and after a second 30 minute treatment with active PEMF or sham treatment. Eligible subjects with painful peripheral diabetic neuropathy will undergo Diabetic Screening (Nerve Conduction Velocity, Skin Perfusion Pressure, Ankle-Brachial Index, and Vibratory Testing) in the index foot prior to randomization. Following the Diabetic Screening tests, subjects will return to the research center for the Enrollment/Randomization Visit and complete measures of pain by completing the Brief Pain Inventory (BPI) and functional assessments. Subjects will then be randomly assigned to one of the two groups; control (sham) or experimental (active) device by a research assistant blinded to the device status. Patients will also be randomly assigned to the sequence order of experimental induced pain tests. The ischemic pain testing (SMET) will always be conducted last. Patients will return to the research center within 7 days after the Enrollment/Randomization Visit where they will be crossed over to the other treatment assignment and be randomly assigned to the sequence order of experimental induced pain tests on the same extremity as previously randomized.
OBJECTIVES: To investigate the prediction of pathologic complete response (pCR) in patients with non-small cell lung cancer (NSCLC) undergoing neoadjuvant immunochemotherapy (NAIC) using quantification of intratumoral heterogeneity from pre-treatment CT image.
METHODS: This retrospective study included 178 patients with NSCLC who underwent NAIC at 4 different centers. The training set comprised 108 patients from center A, while the external validation set consisted of 70 patients from center B, center C, and center D. The traditional radiomics model was contrasted using radiomics features. The radiomics features of each pixel within the tumor region of interest (ROI) were extracted. The optimal division of tumor subregions was determined using the K-means unsupervised clustering method. The internal tumor heterogeneity habitat model was developed using the habitats features from each tumor sub-region. The LR algorithm was employed in this study to construct a machine learning prediction model. The diagnostic performance of the model was evaluated using criteria such as area under the receiver operating characteristic curve (AUC), accuracy, specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV).
RESULTS: In the training cohort, the traditional radiomics model achieved an AUC of 0.778 [95% confidence interval (CI): 0.688-0.868], while the tumor internal heterogeneity habitat model achieved an AUC of 0.861 (95% CI: 0.789-0.932). The tumor internal heterogeneity habitat model exhibits a higher AUC value. It demonstrates an accuracy of 0.815, surpassing the accuracy of 0.685 achieved by traditional radiomics models. In the external validation cohort, the AUC values of the two models were 0.723 (CI: 0.591-0.855) and 0.781 (95% CI: 0.673-0.889), respectively. The habitat model continues to exhibit higher AUC values. In terms of accuracy evaluation, the tumor heterogeneity habitat model outperforms the traditional radiomics model, achieving a score of 0.743 compared to 0.686.
CONCLUSION: The quantitative analysis of intratumoral heterogeneity using CT to predict pCR in NSCLC patients undergoing NAIC holds the potential to inform clinical decision-making for resectable NSCLC patients, prevent overtreatment, and enable personalized and precise cancer management.
Participants randomized to PRK surgery will be referred to a study surgical center. The participant will have a preoperative exam within 7 days prior to surgery and surgery within 60 days after randomization. Participants will continue prescribed 2 hours per day of patching between randomization and the day of surgery.
PROBLEM TO BE SOLVED: To obtain the subject composition of an aromatic substance and a fragrance-emitting substance having high adhesivity and stability and strong smell and taste of a tropical fruit by using a specific 3-acylthiohexyl ester as an active component. SOLUTION: A 3-acyl-thiohexyl ester of the formula I (R<1> and R<2> are each H, an alkyl, furyl, thienyl or an aryl) is used as a component of the subject composition. The compound of the formula I can be used as a racemic mixture, an optically pure form, etc. Especially preferable compounds are 3- propionylthiohexyl propionate, 3-acetylthiohexyl propionate, 3-propionylthiohexyl acetate and 3-acetylthiohexyl acetate. The compound of the formula I can be produced e.g. by esterifying 3-mercaptohexanol of the formula II or 3- mercaptohexyl ester of the formula III. The composition is especially suitable as a fruit composition, fat composition, roast food, yoqurt, ice cream, cake and fruit juice composition.
PURPOSE:To obtain a cosmetic having excellently beautifying effects, useful for preventing and treating stains and freckles, showing excellent emulsion stability and feeling in use, comprising a silicone oil, an L-ascorbic acid and a specific silicone-based surfactant. CONSTITUTION:10-60wt.% silicone oil (e.g. dimethylpolysiloxane) and 0.1-10wt.% water-soluble derivative (e.g. sodium salt of L-ascorbic acid phosphoric ester) are blended with an aqueous phase component and the whole amount of a cosmetic is blended with 40-90wt.% of the aqueous phase component. The blend is mixed with 0 1-10wt.% surfactant selected from a polyoxyalkylene modified silicone, alkyl glyceryl ether-modified silicone and a polyether alkyl-modified silicone. The resulting substance is prepared into a dosage form such as cream, ointment, milky lotion, gel, pack or stick and applicable as a quasi-drug or external preparation.
Participants with episodic TTH and who have already been treated with Neosaldina will be included in the observation period of this study. During the observation period, participants will be administered with Neosaldina 2 tablets, orally in the beginning of the TTH episode, every 6 hours, and at maximum of 8 tablets per day, according to regular clinical practice of the physicians. The participants will be observed in this study from Day 1 until Day 45.
Overactive bladder (OAB) is a common urological disease with a high prevalence in older adult populations. Antimuscarinic drugs have been the most common treatment for OAB for more than a decade, but their anticholinergic side-effects and potential impact on cognitive function among older patients are usually underestimated. This consensus aimed to provide practical recommendations concerning OAB management, with a particular emphasis on older patients. A joint consensus panel was formed by representatives of the Hong Kong Urological Association and the Hong Kong Geriatrics Society. Literature searches regarding OAB and its management were performed in PubMed and Ovid. Several working meetings were held to present and discuss available evidence, develop consensus statements, and vote for the statements. A modified Delphi method was used in this consensus process. To address questions regarding various aspects of OAB, 29 consensus statements were proposed covering the following areas: diagnosis, initial assessment, non-pharmacological treatments, considerations before administration of pharmacological treatments, various pharmacological treatments, combination therapy, and surgical treatment. Twenty-five consensus statements were accepted.
PCT No. PCT/SE94/01048 Sec. 371 Date Jun. 28, 1996 Sec. 102(e) Date Jun. 28, 1996 PCT Filed Nov. 8, 1994 PCT Pub. No. WO95/12991 PCT Pub. Date May 18, 1995The present invention is related to an energy supply composition particularly suitable for use before, during and after physical exertion. The composition is a beverage, or a dry composition therefore, useful as an energy source in situations which demand a large and rapid energy supply to a healthy mammal including man. The beverage comprises an effective amount of alpha-ketoglutaric acid or a water-soluble innocuous salt thereof together with a nutritionally acceptable water-soluble carrier.
A multicenter randomized controlled trial will be performed. Patients usually present with symptoms (e.g., painless hematuria). The urologist will perform cystoscopy and if urothelial cancer of the bladder is suspected, the patient is taken to the operating room for an examination under anesthesia (EUA) and a TURBT. If this shows muscle invasion then conventional staging with CT chest, abdomen, and pelvis is performed. The patient who has TNM Stage T2a-T4a N0-3 M0 is eligible to be enrolled in the trial. Eligible consenting patients will be randomized 2:1 to PET-CT or none (Control). The actual treatment received by the patient will be documented. The primary outcome measure is treatment received.
The application of pulsating negative pressure will be up to 120 minutes long per day. The pulsating negative pressure used will be approximately 40 mm Hg alternating with ambient air pressure, the pulse consisting of 10 seconds of negative pressure followed by 7 seconds of atmospheric pressure.
A system for synthesizing radiopharmaceuticals comprising a stationary process (10) and single use disposable kits (100). The processor has a kit interface (22) with valve actuators and fluidic fittings that interface to a processor interface (102) on the kit containing corresponding rotary valves and fittings. The kit (100) is positioned to the processor with side supports (24) having slots (26) that allow vertical movement of the kit down to support rods (32). Linear actuators (20) translate the kit toward the processor to interface the rotary valves and fittings and, after processing, off the supports (32) so that the kit falls into a container below. Reagent and reactor vessels have a mounting structure (104). Flexible tubing interconnects vales and fittings on the processor interface (102) and vessels on the mounting structure (104). When needed, a reactor vessel heater (42) can be raised and lowered by an actuator (44).
ASA I-II female patients aged over 18 who will undergoing breast reduction surgery will recruit to the study. General anesthesia with sevoflurane and remifentanil will perform to the all patients. Patients will divide into 2 groups. Serratus plane block for group I and serratus plane block+pectointercostal block for Group II will perform bilaterally. Ultrasound guided deep serratus plane block will perform with 0,25% bupivacaine 20 ml at the midaxillary 5. rib, for Group I. At Group II, ultrasound guided deep serratus plane block ( 0,25 %bupivacaine 20 ml) at the midaxillary 5.th rib+ pectointercostal plane block (0,25% bupivacaine 15 ml) at 4-5.th intercostal space will perform bilaterally. Patient controlled analgesia will perform with Morphine ( 1 mg bolus+ 10 min lockout+4 hours limit 10 mg) at postoperative period. Patients will evaluate with visual analogue scale (VAS) for postoperative pain scores till the first 24.th hours. Postoperative pain scores (VAS), morphine consumption and complications will record till the 24.th hours.
PROBLEM TO BE SOLVED: To obtain a clear and stable liquid composition containing a urate oxidase. SOLUTION: This liquid composition comprises a urate oxidase and 0.1-10mg/ml Poloxamer 188 (R) in a buffered aqueous medium (e.g. a sodium phosphate buffer solution). Furthermore, 1-50mg/ml alanine and 1-50mg/ml mannitol are contained therein. The Poloxamer 188 (R) is a block copolymer of ethylene oxide and propylene oxide. The concentration of the buffer solution is 5-100mM and the composition is clear and physically and chemically stable after regulation of the pH to 7.5-8.5 and preservation thereof at 25 deg.C for 48hr to 1 year. The composition can be prepared as a subcutaneous, an intravenous and an intramuscular parenteral injections. The composition is obtained by dissolving the freeze-dried substance containing the urate oxidase in an aqueous solvent.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. 

The data described below reflect pooled data from 5 clinical trials of the Estradiol Transdermal System. A total of 614 women were exposed to the Estradiol Transdermal System for 3 months (193 women at 0.025 mg per day, 201 women at 0.05 mg per day, 194 women at 0.1 mg per day) in randomized, double-blind trials of clinical efficacy versus placebo and versus active comparator. All women were postmenopausal, had a serum estradiol level of less than 20 pg/mL, and a minimum of five moderate to severe hot flushes per week or a minimum of 15 hot flushes per week of any severity at baseline. Included in this table are an additional 25 postmenopausal hysterectomized women exposed to the Estradiol Transdermal System 0.025 mg per day for 6 to 24 months (N=16 at 24 months) in a randomized, double-blind, placebo-controlled study of the Estradiol Transdermal System for the prevention of osteoporosis. 

###  The Estradiol Transdermal System
<P>PROBLEM TO BE SOLVED: To provide a cream-like face cleanser which is free from a polyoxyethylene or polyoxypropylene adduct, has excellent safety, and contains a fatty acid soap.  <P>SOLUTION: This face cleanser is characterized by comprising (1) a fatty acid soap, (2) a polyglycerol fatty acid ester, and (3) diglycerol. The content of the fatty acid constituting the fatty acid soap is preferably 30 to 60 mass% based on the total amount of the cleanser. It is preferable that the contents of palmitic acid and myristic acid are 10 to 20 mass% and 5 to 10 mass%, respectively, based on the total amount of the fatty acids, in the fatty acids constituting the fatty acid soap. It is also preferable to contain decaglycerol fatty acid ester as the polyglycerol fatty acid ester.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention relates to a peptidomimetic STAT protein degrader, a composition and a use thereof. Disclosed are a structure represented by general formula (I), or a stereoisomer thereof, or a stereoisomer mixture thereof or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a use thereof as a STAT protein degrader. The inventor of the present invention has confirmed through experiments that the compound of the present invention can degrade a transcription factor STAT3. The compound of the present invention has obvious proliferation inhibitory activity on MOLM16 and SU-DHL-1 tumor cells. The compound of the present invention has good pharmacokinetic properties. In addition, the compound of the present invention has remarkable anti-tumor efficacy in vivo.